STEMSOFT

STEMSOFT is a leading provider of specialized healthcare information technology solutions designed for the cell therapy, cord blood, and blood and marrow transplantation (BMT) sectors. The company offers a suite of software products, including STEMSOFT Lab, STEMSOFT Clinical, and STEMSOFT Cord, which assist laboratories and clinical facilities in managing complex data and ensuring regulatory compliance. Their platforms are specifically engineered to meet the stringent requirements of FACT and JACIE accreditation standards, streamlining manufacturing and clinical workflows. Originally founded in 1992, STEMSOFT has become a critical infrastructure provider for organizations involved in regenerative medicine and cellular immunotherapy. Following its acquisition by WellSky in 2021, the company operates as part of WellSky Biotherapies, continuing to support the global biotherapy community with integrated data management and quality assurance tools.